ROLE OF VITAMIN D AND RISK OF PROSTATE CANCER

Milind N Dudhane, Umesh Pareek

Abstract


Background: Vitamin D is a secosteroid hormone and well-known for its classical actions in the maintenance of calcium uptake and bone metabolism. Recently, numerous in vitro experiments demonstrated that 1,25-(OH)2D3, the active form of vitamin D, inhibited the growth and differentiation of human prostate cancer cells.

Aim: To estimate vitamin D level in  prostate cancer  patients along with increasing risk.

 Material & Methods : 100 samples along with control were analysed by cobas e-411 for Vitamin D and PSA.

Results:  we have found Higher risk of prostate cancer who having low vitamin D.

Conclusion: it’s time to aware people for supplementation of Vitamin D, so we can prevent  for the same.

 


Full Text:

PDF

References


Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG, de Bono JS. Prostate cancer. Lancet. 2016; 387:70-82. doi: 10.1016/S0140-6736(14)61947-4.

Sharma N, Mangukiya K, Mali KL, Pareek UK and Sharma AK: Comparative Study of the Status of Vitamin D3 in Young Office Working Women and Housewives in Udaipur, Rajasthan. Int J Pharm Sci Res 2015; 6(5): 2197-00.doi: 10.13040/IJPSR.0975-8232.6(5).2197-00.

Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA. 2014; 311:1143-9. doi: 10.1001/jama.2014.2085.

Hu MB, Bai PD, Wu YS, Zhang LM, Xu H, Na R, Jiang HW, Ding Q. Higher body mass index increases the risk for biopsy-mediated detection of prostate cancer in Chinese men. PLoS One. 2015; 10:e0124668. doi: 10.1371/journal. pone.0124668.

Wang M, Hu RY, Wu HB, Pan J, Gong WW, Guo LH, Zhong JM, Fei FR, Yu M. Cancer risk among patients with type 2 diabetes mellitus: a population-based prospective study in China. Sci Rep. 2015; 5:11503. doi: 10.1038/ srep11503.

Ferraldeschi R, Welti J, Luo J, Attard G, de Bono JS. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene. 2015; 34:1745-57. doi: 10.1038/onc.2014.115.

Fallowfield L, Payne H, Jenkins V. Patient-reported outcomes in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol. 2016; 13:643-50. doi: 10.1038/ nrclinonc.2016.100.

Wadosky KM, Koochekpour S. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget. 2016; 7:64447-70. doi: 10.18632/oncotarget.10901.

Gueron G, De Siervi A, Vazquez E. Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer Prostatic Dis. 2012; 15:213-21. doi: 10.1038/pcan.2011.64.

Elder CJ, Bishop NJ. Rickets. Lancet. 2014; 383:1665-76. doi: 10.1016/S0140-6736(13)61650-5.

Munns CF, Shaw N, Kiely M, Specker BL, Thacher TD, Ozono K, Michigami T, Tiosano D, Mughal MZ, Mäkitie O, Ramos-Abad L, Ward L, DiMeglio LA, et al. Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. J Clin Endocrinol Metab. 2016; 101:394-415. doi: 10.1210/jc.2015-2175.

Bernichtein S, Pigat N, Barry Delongchamps N, Boutillon F, Verkarre V, Camparo P, Reyes-Gomez E, Méjean A, Oudard SM, Lepicard EM, Viltard M, Souberbielle JC, Friedlander G, et al. Vitamin D3 prevents calcium-induced progression of early-stage prostate tumors by counteracting TRPC6 and calcium sensing receptor upregulation. Cancer Res. 2017; 77:355-65. doi: 10.1158/0008-5472.CAN-16-0687.

Luo W, Yu WD, Ma Y, Chernov M, Trump DL, Johnson CS. Inhibition of protein kinase CK2 reduces Cyp24a1 expression and enhances 1,25-dihydroxyvitamin D(3) antitumor activity in human prostate cancer cells. Cancer Res. 2013;73:2289-97. doi: 10.1158/0008-5472. CAN-12-4119.

Koike H, Morikawa Y, Sekine Y, Matsui H, Shibata Y, Suzuki K. Survivin is associated with cell proliferation and has a role in 1a,25-dihydroxyvitamin D3 induced cell growth inhibition in prostate cancer. J Urol. 2011; 185:1497-503. doi: 10.1016/j.juro.2010.12.005.


Refbacks

  • There are currently no refbacks.